BCL2L1 and acute myeloid leukemia: MCL1/BCL2L1 was also differentially expressed and higher in the relapsed than the primitive clone present at diagnosis (p-value < 0.001 for both Dx-prim vs. RI-mono and Dx-mono vs. RI-mono), differently from relapsed AML samples from conventional chemotherapy (Supplementary Fig. S13D, E).